Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Delayed Data
As of Oct 21
 +0.42 / +8.20%
Today’s Change
Today|||52-Week Range
Main Biotech Indices Surrender Yesterday's Gains
Oct 21 / TheStreet.com - Paid Partner Content
How Risky Is Merrimack Pharmaceuticals Stock?
Oct 13 / MotleyFool.com - Paid Partner Content
Shire Cancer Drug Onivyde Receives EU Marketing Approval
Oct 19 / Zacks.com - Paid Partner Content
Merrimack's Onivyde Positive in Pancreatic Cancer Study
Oct 12 / Zacks.com - Paid Partner Content
Will Positive Phase 3 Results Get Merrimack Back on Track?
Oct 14 / MotleyFool.com - Paid Partner Content
Why Merrimack Pharmaceuticals Inc. Rose 38% in September
Oct 10 / MotleyFool.com - Paid Partner Content